Lonza to establish Cell- and Gene-Therapy Centers of Excellence to accelerate growth

Swiss pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN) says it will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.

This decision advances Lonza's strategy of being one of the world’s leading, integrated, value-added solutions providers along the healthcare continuum, the company explains. To further improve its support to customers, Lonza’s Cell- and Gene-Therapy Centers of Excellence will include Lonza sites that are already serving customers and their patients with these innovative technologies.

The Lonza sites in Pearland, Texas (USA) and Geleen/Maastricht (Netherlands) will offer a fully integrated range of cell- and gene-therapy services including process and analytical development, clinical product supply and commercial product supply. Lonza’s sites in Portsmouth, New Hampshire (USA) and Singapore will serve both as clinical and commercial manufacturing sites.